Loading IPO Details...
Upcoming IPOs
Healthcare · Listed on BSE , NSE · 10 Aug 2026 - 12 Aug 2026
Jagat JoshiIncorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour.
Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic collaborations, while continuously expanding its diagnostics product pipeline through strong in-house R&D capabilities.
| Date & Time | GMP (₹) | Est. Listing Price | Est. Gain (%) | Est. Profit / Lot (₹) |
|---|---|---|---|---|
| 17-Aug-2026 12:00 PM | +₹120 | ₹927 | +14.87% | ₹2,160 |
| 14-Aug-2026 12:00 PM | +₹156 | ₹963 | +19.33% | ₹2,808 |
| 13-Aug-2026 12:00 PM | +₹156 | ₹963 | +19.33% | ₹2,808 |
| 12-Aug-2026 12:00 PM | +₹138 | ₹945 | +17.10% | ₹2,484 |
| 11-Aug-2026 12:00 PM | +₹127 | ₹934 | +15.74% | ₹2,286 |
| 10-Aug-2026 12:00 PM | +₹132 | ₹939 | +16.36% | ₹2,376 |
| 08-Aug-2026 12:00 PM | +₹180 | ₹987 | +22.30% | ₹3,240 |
| 07-Aug-2026 12:00 PM | +₹220 | ₹1027 | +27.26% | ₹3,960 |
| 06-Aug-2026 12:00 PM | +₹170 | ₹977 | +21.07% | ₹3,060 |
| Category | Subscription (x) | Shares Offered | Shares bid for | Total Amount (₹ Cr) |
|---|---|---|---|---|
| Anchor | 1.00x | 34,87,717 | 34,87,717 | ₹281.46 Cr |
| QIB (Ex. Anchor) | 186.39x | 23,25,145 | 43,33,82,148 | ₹34,973.94 Cr |
| NII | 49.80x | 17,43,860 | 8,68,40,604 | ₹7,008.04 Cr |
| bNII > ₹10L | 50.82x | 11,62,573 | 5,90,76,594 | ₹4,767.48 Cr |
| sNII < ₹10L | 47.76x | 5,81,287 | 2,77,64,010 | ₹2,240.56 Cr |
| Retail | 12.97x | 40,69,005 | 5,27,70,906 | ₹4,258.61 Cr |
| Employees | 13.28x | 20,519 | 2,72,466 | ₹21.99 Cr |
| Total | 49.52x | 1,16,46,246 | 57,67,53,841 | ₹46,544.03 Cr |
| Period Ended | 31 MAR 2026 | 31 MAR 2025 | 31 MAR 2024 |
|---|---|---|---|
| Total Income | 1455.17 | 1027.94 | 840.66 |
| Profit After Tax | 164.14 | 138.58 | 83.54 |
| EBITDA | 328.24 | 256.64 | 185.09 |
| NET Worth | 1144.68 | 952.95 | 807.94 |
| Reserves and Surplus | 1148.84 | 990.84 | 845.48 |
| Total Borrowing | 412.64 | 123.16 | 174.58 |
| Company Name | EPS (₹) | P/E (x) | NAV (₹) | RoNW (%) | Income (₹ Cr) |
|---|---|---|---|---|---|
| Vijaya Diagnostics Centre Limited | 16.81 | 81.02 | 93.02 | 18.07 | 814.20 |
| Metropolis Healthcare Limited | 9.19 | 63.72 | 72.98 | 12.56 | 1,645.85 |
| Dr. Lal Pathlabs Limited | 30.24 | 62.20 | 145.00 | 20.78 | 2,762.91 |
| Poly Medicure Limited | 31.79 | 52.61 | 306.45 | 10.37 | 1,875.26 |
Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Exxora Trading LLP. is the company's promoter of Molbio Diagnostics.
| Particular | Pre IPO | Post IPO |
|---|---|---|
| Promoter and Promoter Group | 44.89% | 41.29% |
| Others* | 55.11% | 58.71% |
Join the discussion
Please sign in to leave a comment or reply.